ChemicalBook > Product Catalog > API > Nervous system drugs > Drug Metabolism in Human Brain > Piracetam
Basic information Overview Description Indication Pharmacological effects Pharmacokinetics Mode of action Toxicity Contradictions and drug interactions Side effects References Safety Related Supplier
Piracetam Chemical Properties
- Melting point:151-152,5 C
- Boiling point:259.72°C (rough estimate)
- Density 1.2298 (rough estimate)
- refractive index 1.5010 (estimate)
- storage temp. Store at RT
- solubility Freely soluble in water, soluble in ethanol (96 per cent). It shows polymorphism (5.9).
- form neat
- color Crystals from isopropanol
- CAS DataBase Reference7491-74-9(CAS DataBase Reference)
- NIST Chemistry ReferencePiracetam(7491-74-9)
Piracetam Usage And Synthesis
- OverviewPiracetam is a cyclic derivative of the neurotransmitter gamma-aminobutyric acid(GABA), originally marketed in 1971 by UCB Pharma. It was the first “nootropic” drug, an agent that acts on cognitive function without causing sedation or stimulation. While the mechanisms of action of piracetam have yet to be fully elucidated, it influences neuronal and vascular functions. Furthermore, vascular effects are peripheral as well as central, meaning that the clinical benefit of piracetam goes beyond its nootropic features. Indeed, piracetam is now indicated for use in vertigo, dyslexia, cortical myoclonus and sickle cell anemia in addition to age-related cognitive disorders. Piracetam has been available for over 40 years. Its efficacy has been recorded in cognitive disorders and dementia, vertigo, cortical myoclonus, dyslexia, and sickle cell anemia, however, the clinical application in these conditions is not yet established. Piracetam also has effects on the vascular system through reducing erythrocyte adhesion to vascular endothelium, hinder vasospasm and facilitate microcirculation.
Figure 1 The chemical structure of piracetam ;
- DescriptionFound commercially under the name Nootropil® (UCB Pharma, Slough, UK) Piracetam is available in tablet form (800 mg) and as oral solution (333.3 mg/ mL). Piracetam is initially prescribed at a dose of 7.2 g daily, divided into 2 or 3 doses, and can be gradually increased in steps of 4.8 g daily every 3– 4 days up to a maximum dose of 20 g daily (subsequently, attempts should be made to reduce the dose of concurrent therapy). Piracetam is a nootropic agent with an indication as adjunctive treatment for myoclonus of cortical origin, as well as tardive dyskinesia. However, piracetam is not approved by the FDA for any medical use in the USA. Piracetam should not be prescribed in patients with Huntington disease, those with serious kidney problems, or patients who have experienced a brain haemorrhage. Bleeding problems are a further caution to be taken into account. Most common adverse effects are hyperkinesia, irritability, and weight gain; less commonly, patients can report asthenia, depression, and drowsiness. Although there is little evidence for piracetam’s efficacy in terms of long- term benefits for the treatment of mild cognitive impairments, recent studies showed that it is effective in the treatment of cognitive disorders of cerebrovascular and traumatic origins. With regard to piracetam’s behavioural profile, its beneficial effects on lowering depression and anxiety appear to be higher than its positive effects on memory.
- IndicationIt is indicated in the case of adult patients suffering from myoclonus of cortical origin, irrespective of aetiology, and should be used in combination with other anti-myoclonic therapies.
- Pharmacological effectsNeuronal effects
Piracetam has important effects on neurotransmission that are not limited to any one type of neurotransmitter. It has been shown to influence cholinergic[3,4], serotoninergic, noradrenergic, and glutamatergic systems. The modulation of these systems by piracetam does not result from direct receptor agonism or antagonism(piracetam has no affinity for these receptors; Ki > 10 μM). Instead, piracetam appears to increase the number of postsynaptic receptors and or restore the function of these receptors. The effect of piracetam on cholinergic and glutamatergic systems is likely to be particularly relevant to its clinical benefit in cognitive disorders, given the increasing evidence that dysfunction in these systems may be related to cognitive decline[9,10]. Preclinical studies have shown that piracetam appears to offer neuroprotective benefits. This is consistent with the suggestion that interactions between piracetam and membrane lipids may decrease the risk of membrane fusion. Piracetam has been shown to reduce the incidence of animal death following barbiturate overdose, and to protect against morphological changes related to long-term alcohol use. The anticonvulsant action of piracetam has also been documented in animal studies. Administration of piracetam prior to a convulsant stimulus reduces seizure severity in rats prone to audiogenic attacks.
Studies suggest that piracetam exerts a number of effects on erythrocytes, such as decreased adhesion to endothelium. These effects are likely to facilitate movement of erythrocytes through the circulation. Studies have also indicated that piracetam exerts an effect on blood vessels. For example, in vitro, 2 mg/kg piracetam decreased the time taken for rabbit pial vessels to return to normal diameter following a period of induced arteriolar spasm(10.4 vs. 5.1 min for 0.02 and 2 mg/kg of piracetam, respectively). Piracetam may also influence blood coagulation. In healthy humans, a single dose of piracetam(3.2 to 9.6 g) reduced plasma levels of fibrinogen and von Willebrand factor in a dose-dependent manner by up to 40%. Enhanced cerebral blood flow has been reported following piracetam treatment in hypotensive cats and in humans with acute cerebral ischemia[17,18]. Additionally, piracetam appears to influence microcirculation at the peripheral level. Following treatment with piracetam, renal blood flow was significantly greater in ischemically damaged rat kidneys relative to controls, and, in a separate experiment, blood flow significantly increased in the cochlea of guinea pigs without any marked change in blood pressure.
- PharmacokineticsPiracetam is rapidly absorbed. Following oral administration, peak plasma concentrations in fasting subjects are achieved in approximately 30 min. Following a single oral dose of 3.2 g, peak concentration is typically 84 ug/mL. Oral formulations of piracetam are extensively absorbed with a bioavailability close to 100%. No metabolites of piracetam have yet been discovered and the drug is excreted unchanged in the urine by glomerular filtration. While food does not affect the extent of absorption of piracetam, it does decrease the maximal plasma concentration of the drug by 17% and prolong Tmax to 1.5 h. Piracetam crosses blood–brain and placental barriers and is found in all tissues, except adipose tissue. The uptake into the brain is less rapid than into the circulation, and, at nearly 8 h, half-life in cerebrospinal fluid is longer than in plasma(about 5 h).
- Mode of actionAlthough piracetam is a derivative of GABA, its mechanism of action appears to be unrelated to the properties of this neurotransmitter. While the exact mode of action of piracetam is a matter of debate, there is increasing evidence that its underlying effect is to restore cell membrane fluidity. Cell membranes comprise a bilayer of lipid molecules interspersed with protein molecules. These membranes are fluid structures in which the molecules comprising the membrane can diffuse while maintaining this overall arrangement. Membrane fluidity is believed to be important for a number of activities including membrane transport, enzyme activity, chemical secretion, and receptor binding and stimulation[23,24]. Piracetam can have direct interaction with the membrane. The resultant mobile drug–lipid complexes are thought to induce the reorganization of lipids, which may influence membrane function and fluidity. Studies have also demonstrated that piracetam influences membrane fluidity, particularly when normal fluidity is compromised, as is often seen during aging. Several in vitro studies have assessed fluidity during piracetam treatment using anisotropy of membrane-bound DPH[1,6-diphenyl-1,3,5-hexatriene]. Incubation with piracetam restored fluidity in brain membranes of elderly mice with diminished fluidity but had no effect on brain membranes of younger mice with normal fluidity. Similarly, in other studies using in vitro anisotropy techniques, fluidity was restored in the membranes of aged rat and aged human brains following incubation with piracetam. Similar effects were observed in hippocampal membranes from patients with Alzheimer’s disease. This improvement of fluidity coincided with significantly improved avoidance learning. No effect of piracetam on learning or membrane fluidity was found in young rats receiving piracetam. Through restored membrane fluidity, piracetam can promote restored neurotransmission such as glutamatergic and cholinergic systems, enhances neuroplasticity and mediates neuroprotective and anticonvulsant effects at the neuronal level. It has also been found that piracetam can also improves the fluidity of platelet membranes and decreases adhesion of erythrocytes to cell wall as well as reduces vasospasm which in turn improves microcirculation including cerebral and renal blood flow[23,24].
- ToxicityPiracetam is remarkably well tolerated. In preclinical trials, no irreversible toxicity was reported in mice, rats or dogs receiving single oral doses of up to 10 g/kg. In a pooled analysis of 91 double-blind, placebo-controlled studies, hyperkinesia, weight gain, nervousness, somnolence, depression and asthenia were slightly increased with piracetam, although the incidence of each of these events was less than 2%.
- Contradictions and drug interactionsDue to its renal clearance, piracetam dose should be adjusted in patients with renal insufficiency and the drug is contraindicated in patients with end-stage renal disease. Piracetam should not be prescribed to patients with cerebral hemorrhage. While reproductive studies in animals have not identified any risk to the fetus, studies in humans have not been conducted and so the use of piracetam in pregnant or lactating women should be avoided. Piracetam is neither metabolized by the liver nor bound to plasma albumin. The potential for drug–drug interactions is, therefore, low. Although piracetam enhances the anticonvulsant effects of carbamazepine, no interactions with sodium valproate have been reported. There are no known interactions of piracetam with any other drugs.
- Side effectsDespite that piracetam is regarded as a relatively safe nootropic, some users may still experience side effects and adverse reactions. The severity and number of side effects experienced from piracetam is subject to significant individual variation. One user may not perceive any side effects, while another may notice severe adverse reactions. Of all those reported piracetam side effects, the most common include: nervousness, increased body movements(hyperkinesia), and weight gain. Some rare cases may also include agitation, anxiety, brain fog, cognitive impairment, depression, fatigue, hemocrit/hemoglobin levels change, headaches, hyperkinesia, insomnia, irritability, libido increase, lightheadedness, muscle spasms, nausea, restlessness, shakiness, sleep disturbances, speech impairment, somnolence, sweating, visual change and weakness.
- Giurgea C. Vers une pharmacologie de l’activite? inte?grative du cerveau. Tentative du concept nootrope en psychopharmacologie. [Towards an integrative pharmacology of the activity of the brain. Attempt at the nootropic concept in psychopharmacology]. Actual Pharmacol[Paris] 1972;25:115–176.
- Winnicka, K., Tomasiak, M., & Bielawska, A.. Piracetam--an old drug with novel properties? Acta Poloniae Pharmaceutica, 62(5], 405.
- Mu?ller WE. Age related quantitative and qualitative receptor changes and pharmacological reactivity. In: Racagni G, Mendlewicz J, Eds. Treatment of age-related cognitive dysfunction: Pharmacological and clinical evaluation. Int Acad Biomed Drug Res. Basel: Karger 1992;2:35–40.
- Pilch H, Mu?ller WE. Piracetam elevates muscarinic cholinergic receptor density in the frontal cortex of aged but not of young mice. Psychopharmacology 1988;94:74–78.
- Valzelli L, Bernasconi S, Sala A. Piracetam activity may differ according to the age of the recipient mouse. Int Pharmacopsychiatry 1980;15:150–156.
- Olpe H-R, Steinmann MW. The activating action of vincamine, piracetam and hydergine on the activity of the noradrenergic neurons of the locus coeruleus. Behav Neural Biol 1981;33:249–251.
- Cohen SA, Mu?ller WE. Effects of piracetam on N-methyl-D-aspartate receptor properties in the aged mouse brain. Pharmacology 1993;47:217–222
- Gualtieri F, Manetti D, Romanelli MN, Ghelardini C. Design and study of piracetam-like nootropics, controversial members of the problematic class of cognition-enhancing drugs. Curr Pharm Des 2002;8:125–138.
- Segovia G, Porras A, Del Arco A, Mora F. Glutamatergic neurotransmission in aging: A critical perspective. Mech Ageing Dev 2001;122:1–29.
- Terry AV Jr, Buccafusco JJ. The cholinergic hypothesis of age and Alzheimer’s disease-related cognitive deficits: Recent challenges and their implications for novel drug development. J Pharmacol Exp Ther 2003; 306:821–827.
- Mingeot-Leclercq M-P, Lins L, Bensliman M, et al. Piracetam inhibits the lipid-destabilising effect of the amyloid peptide Aa? C-terminal fragment. Biochim Biophys Acta 2003;1609:28–38.
- Brandao F, Paula-Barbosa MM, Cadete-Leite A. Piracetam impedes hippocampal neuronal loss during withdrawal after chronic alcohol intake. Alcohol 1995;12:279–288.
- Benesova O. The effects of nootropic drugs on the susceptibility to audiogenic seizures in rats. Act Nerv Super[Praha] 1980;22:192–193.
- Nalbandian RM, Henry RL, Burek CL, et al. Diminished adherence of sickle erythrocytes to cultured vascular endothelium by piracetam. Am J Hematol 1983;15:147–151.
- Reuse-Blom S. Microcirculation of the pial vessels in the rabbit. Acta Cardiol 1979;34:35–36.
- Moriau M, Crasborn L, Lavenne-Pardonge E, Von Frenckell R, Col-Debeys C. Platelet anti-aggregant and rheological properties of piracetam. Arzneimittelforschung 1993;43:110–118.
- Herrschaft H. The effect of piracetam on global and regional cerebral blood flow in acute cerebral ischemia of man. Med Klin 1978;73:195–202.
- Sato M, Heiss WD. Effect of piracetam on cerebral blood flow and somatosensory evoked potential during normotension and hypotensive ischemia in cats. Arzneimittelforschung 1985;35:790–792.
- Gianello P, Janssen T, Chatzopoulos C, et al. Beneficial effect of piracetam on renal blood flow in ischemically injured kidneys in the rat. Transplant Proc 1988;20:914–916.
- Maass B, Soetanto R. Pru?fung der Wirkung von Piracetam auf die Wasserstoff — Clearance am Innenohr [Examination of the effect of piracetam on the hydrogen clearance to the inner ear]. Laryngorhinootologie 1988;67:132–135.
- Gobert JG. Gene?se d’un me?dicament: le piracetam. Me?tabolisation et recherche biochimique. [Genesis of the drug piracetam. Metabolism and biochemical research]. J Pharm Belg 1972;27:281–304.
- Gobert JG, Baltes EL. Availability and plasma clearance of piracetam in man. Farmaco 1977;3:84–91.
- Alberts B, Bray D, Lewis J, et al. Molecular biology of the cell. Chapter 10. 3rd Edition. New York: Garland publishing Inc., 1994.
- Crews FT. Effects of membrane fluidity on secretion and receptor stimulation. Psychopharmacol Bull 1982; 18:135–143.
- Peuvot J, Schank A, Deleers M, Brasseur R. Piracetam-induced changes to membrane physical properties. A combined approach by 31P nuclear magnetic resonance and conformational analysis. Biochem Pharmacol 1995;50:1129–1134.
- Scheuer K, Stoll S, Paschke U, Weigel R, Mu?ller WE. N-methyl-D-aspartate receptor density and membrane fluidity as possible determinants of the decline of passive avoidance performance in aging. Pharmacol Biochem Behav 1995;50:65–70.
- Mu?ller WE, Koch S, Scheuer K, Rostock A, Bartsch R. Effects of piracetam on membrane fluidity in the aged mouse, rat and human brain. Biochem Pharmacol 1997;53:135–140.
- Eckert GP, Cairns NJ, Mu?ller WE. Piracetam reverses hippocampal membrane alterations in Alzheimer’s disease. J Neural Transm 1999;106:757–761.
- Brown P, Steiger MJ, Thompson PD, et al. Effectiveness of piracetam in cortical myoclonus. Mov Disord 1993;8:63–68.
- Chemical PropertiesWhite Solid
- UsesNootropic; cortical myoclonus.
- Biological ActivityNootropic that displays cognitive enhancing properties. Proposed to enhance neurotransmission via modulation of ion flux; potentiates Na + influx through AMPA receptors. Facilitates efficiency of cholinergic neurotransmission at muscarinic receptors.
- Safety ProfileMildly toxic by ingestion. Whenheated to decomposition it emits toxic fumes of NOx.
- Purification MethodsThis typical nootropic (Alzheimer) drug modulates Na flux in AMPA receptors and is purified by recrystallisation from isoPrOH. [Gouilaev & Senning Brain Research Rev 19 180 1994.]
Piracetam Preparation Products And Raw materials
- Company Name:ChemStrong Scientific Co.,Ltd Gold
- Tel:15920483169 0755-66853366-
- Company Name:J & K SCIENTIFIC LTD.
- Tel:400-666-7788 010-82848833-
- Company Name:3B Pharmachem (Wuhan) International Co.,Ltd.
- Tel:18930552037 821-50328103-801
- Company Name:Chembest Research Laboratories Limited
- Company Name:TAIYUAN RHF CO.,LTD.
- Tel:+86 351 7031519